Vectors for molecule delivery to CD11b expressing cells
US10004794B2 · kind B2 · utility
0Cited by
17References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 8, 2016 |
| Grant date | Jun 26, 2018 |
| Priority date | — |
| Expiry date | Jun 8, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.